164 related articles for article (PubMed ID: 38372795)
1. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract][Full Text] [Related]
2. Nontoxic virus nanofibers improve the detection sensitivity for the anti-p53 antibody, a biomarker in cancer patients.
Pan P; Wang Y; Zhu Y; Gao X; Ju Z; Qiu P; Wang L; Mao C
Nano Res; 2015 Nov; 8(11):3562-3570. PubMed ID: 27818740
[TBL] [Abstract][Full Text] [Related]
3. Development of a phage display-mediated immunoassay for the detection of vascular endothelial growth factor.
Rezaei ZS; Shahangian SS; Hasannia S; Sajedi RH
Anal Bioanal Chem; 2020 Nov; 412(27):7639-7648. PubMed ID: 32876721
[TBL] [Abstract][Full Text] [Related]
4. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
5. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
6. Antibodies and Engineered Antibody Fragments against M13 Filamentous Phage to Facilitate Phage-Display-Based Molecular Breeding.
Kiguchi Y; Oyama H; Morita I; Katayama E; Fujita M; Narasaki M; Yokoyama A; Kobayashi N
Biol Pharm Bull; 2018; 41(7):1062-1070. PubMed ID: 29962401
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
8. Rapid and reliable ultrasensitive detection of pathogenic H9N2 viruses through virus-binding phage nanofibers decorated with gold nanoparticles.
Hou J; Qian X; Xu Y; Guo Z; Thierry B; Yang CT; Zhou X; Mao C
Biosens Bioelectron; 2023 Oct; 237():115423. PubMed ID: 37311406
[TBL] [Abstract][Full Text] [Related]
9. Construction of helper plasmid-mediated dual-display phage for autoantibody screening in serum.
Rajaram K; Vermeeren V; Somers K; Somers V; Michiels L
Appl Microbiol Biotechnol; 2014; 98(14):6365-73. PubMed ID: 24764015
[TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
11. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
12. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies that recognise filamentous phage: tools for phage display technology.
Dente L; Cesareni G; Micheli G; Felici F; Folgori A; Luzzago A; Monaci P; Nicosia A; Delmastro P
Gene; 1994 Oct; 148(1):7-13. PubMed ID: 7926840
[TBL] [Abstract][Full Text] [Related]
14. Phage as a Genetically Modifiable Supramacromolecule in Chemistry, Materials and Medicine.
Cao B; Yang M; Mao C
Acc Chem Res; 2016 Jun; 49(6):1111-20. PubMed ID: 27153341
[TBL] [Abstract][Full Text] [Related]
15. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
[TBL] [Abstract][Full Text] [Related]
16. Selectively Suppressing Tumor Angiogenesis for Targeted Breast Cancer Therapy by Genetically Engineered Phage.
Li Y; Qu X; Cao B; Yang T; Bao Q; Yue H; Zhang L; Zhang G; Wang L; Qiu P; Zhou N; Yang M; Mao C
Adv Mater; 2020 Jul; 32(29):e2001260. PubMed ID: 32495365
[TBL] [Abstract][Full Text] [Related]
17. Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF.
Baggio C; Ramaschi GE; Oliviero F; Ramonda R; Sfriso P; Trevisi L; Cignarella A; Bolego C
Biomed Pharmacother; 2023 Jun; 162():114670. PubMed ID: 37068331
[TBL] [Abstract][Full Text] [Related]
18. Modified Filamentous Bacteriophage as a Scaffold for Carbon Nanofiber.
Szot-Karpińska K; Golec P; Leśniewski A; Pałys B; Marken F; Niedziółka-Jönsson J; Węgrzyn G; Łoś M
Bioconjug Chem; 2016 Dec; 27(12):2900-2910. PubMed ID: 27748604
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
20. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
